Manatt Health October 31, 2023
Adam M. Finkelstein

The Center for Medicare and Medicaid Innovation (CMMI) has provided new updates on CMS’ planned initiatives to address prescription drug costs in a blog post from Director Liz Fowler. One test, the Accelerating Clinical Evidence Model, appears to have stalled, while progress continues on other projects.

The post came on the one-year anniversary of Executive Order 14087 in which President Joe Biden ordered Secretary Xavier Becerra to consider selecting Innovation Center models for testing focused on lowering drug costs and increasing access. That order in turn led to a January 2023 report by the Department of Health and Human Services (HHS) selecting three models for testing and announcing next steps for their development and design. The blog post describes the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Govt Agencies, Insurance, Medicare, Payment Models, Pharma, Pharma / Biotech, Value Based
CMS proposes new guardrails on Medicare Advantage prior authorizations, marketing
CMS finalizes new kidney transplant model: 10 things to know
CMS' proposed changes to Medicare Advantage: 10 things to know
Medicare Advantage Plans' Prior Auth Rules Would Be Made Public Under CMS Proposal
Prior authorizations, pharmacy transparency, vertical integration all part of the Medicare 2026 rule

Share This Article